





^aFor information on approved uses, please refer to approved product labeling. ^bIncludes Celgene-supported studies. ^cIn the US, regulatory approval is based on pivotal phase II data; phase III program ongoing. In collaboration with MorphoSys AG. IIIOphoSys and IIIophosys eln collaboration with Acceleron Pharma. Acceleron Pharma. In collaboration with Agios Pharmaceuticals, Inc. > agios eln collaboration with Epizyme, Inc. (Epizyme)





^aFor information on approved uses, please refer to approved product labeling. ^bIncludes Celgene-sponsored and Celgene-supported studies. ^cFiling for regulatory approval based on pivotal phase II data. ^dIn collaboration with Acceleron Pharma.

ACCELERON





^aFor information on approved uses, please refer to approved product labeling. ^bIncludes Celgene-sponsored and Celgene-supported studies. ^cTrial conducted by licensee partner, Taiho Pharmaceuticals Co. Ltd. ^dRegulated under Section 361 of the Public Health Service Act. ^eProcessed for Alliqua Biomedical by Celgene Cellular Therapeutics. ^f510(k) device manufactured for Alliqua Biomedical by Celgene Cellular Therapeutics.